These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 32894792)

  • 1. Using real-world evidence for pharmacovigilance and drug safety-related decision making by a resource-limited health authority: 10 years of experience in Taiwan.
    Chen WW; Lin CW; Huang WI; Chao PH; Gau CS; Hsiao FY
    Pharmacoepidemiol Drug Saf; 2020 Nov; 29(11):1402-1413. PubMed ID: 32894792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Building an active medical product safety surveillance system in Taiwan: Adaptation of the U.S. Sentinel System common data model structure to the National Health Insurance Research Database in Taiwan.
    Huang K; Lin FJ; Ou HT; Hsu CN; Huang LY; Wang CC; Toh S
    Pharmacoepidemiol Drug Saf; 2021 Jan; 30(1):97-101. PubMed ID: 33146908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation.
    Pacurariu A; Plueschke K; McGettigan P; Morales DR; Slattery J; Vogl D; Goedecke T; Kurz X; Cave A
    BMJ Open; 2018 Sep; 8(9):e023090. PubMed ID: 30185579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacovigilance systems and databases in Korea, Japan, and Taiwan.
    Kimura T; Matsushita Y; Yang YH; Choi NK; Park BJ
    Pharmacoepidemiol Drug Saf; 2011 Dec; 20(12):1237-45. PubMed ID: 21936017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An OMOP-CDM based pharmacovigilance data-processing pipeline (PDP) providing active surveillance for ADR signal detection from real-world data sources.
    Shin H; Lee S
    BMC Med Inform Decis Mak; 2021 May; 21(1):159. PubMed ID: 34001114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using resources for scientific-driven pharmacovigilance: from many product safety documents to one product safety master file.
    Furlan G
    Drug Saf; 2012 Aug; 35(8):615-22. PubMed ID: 22788233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nintedanib and ischemic colitis: Signal assessment with the integrated use of two types of real-world evidence, spontaneous reports of suspected adverse drug reactions, and observational data from large health-care databases.
    Chandler RE
    Pharmacoepidemiol Drug Saf; 2020 Aug; 29(8):951-957. PubMed ID: 32399991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decision making in drug safety-a literature review of criteria used to prioritize newly detected safety issues.
    Pacurariu AC; Coloma PM; Gross-Martirosyan L; Sturkenboom MC; Straus SM
    Pharmacoepidemiol Drug Saf; 2017 Mar; 26(3):327-334. PubMed ID: 27878889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world evidence to support regulatory decision making: New or expanded medical product indications.
    Franklin JM; Liaw KL; Iyasu S; Critchlow CW; Dreyer NA
    Pharmacoepidemiol Drug Saf; 2021 Jun; 30(6):685-693. PubMed ID: 33675248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Learning the effects of psychotropic drugs during pregnancy using real-world safety data: a paradigm shift toward modern pharmacovigilance.
    Lupattelli A; Spigset O; Nordeng H
    Int J Clin Pharm; 2018 Aug; 40(4):783-786. PubMed ID: 29948744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Collection of Data on Adverse Events Related to Medicinal Products: A Survey Among Registries in the ENCePP Resources Database.
    Plueschke K; Jonker C; Strassmann V; Kurz X
    Drug Saf; 2022 Jul; 45(7):747-754. PubMed ID: 35729468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using real-world healthcare data for pharmacovigilance signal detection - the experience of the EU-ADR project.
    Patadia VK; Coloma P; Schuemie MJ; Herings R; Gini R; Mazzaglia G; Picelli G; Fornari C; Pedersen L; van der Lei J; Sturkenboom M; Trifirò G;
    Expert Rev Clin Pharmacol; 2015 Jan; 8(1):95-102. PubMed ID: 25487079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk undermined in the bilateral pharmaceutical regulatory system in Taiwan.
    Wang HP; Wang CL
    J Food Drug Anal; 2018 Apr; 26(2S):S3-S11. PubMed ID: 29703384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacovigilance in Israel - tools, processes, and actions.
    Schwartzberg E; Berkovitch M; Dil Nahlieli D; Nathan J; Gorelik E
    Isr J Health Policy Res; 2017 Aug; 6(1):29. PubMed ID: 28760141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic disorders in the WHO pharmacovigilance database VigiBase from 2010 to 2020.
    Ortland I; Mirjalili M; Kullak-Ublick GA; Peymani P
    Swiss Med Wkly; 2021 May; 151():w20503. PubMed ID: 34000058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of drugs safety signals that predict safety related product information update.
    Insani WN; Pacurariu AC; Mantel-Teeuwisse AK; Gross-Martirosyan L
    Pharmacoepidemiol Drug Saf; 2018 Jul; 27(7):789-796. PubMed ID: 29797381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacovigilance in China: development and challenges.
    Zhao Y; Wang T; Li G; Sun S
    Int J Clin Pharm; 2018 Aug; 40(4):823-831. PubMed ID: 30051225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in reporting drug-associated liver injuries in Taiwan: a focus on amiodarone.
    Ye JH; Ho YF; On AW; Chen WW; Huang YM; Huang WI; Tang YW
    Int J Clin Pharm; 2018 Aug; 40(4):911-920. PubMed ID: 30051228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse Drug Reactions during Real-Life Use of Direct Oral Anticoagulants in Italy: An Update Based on Data from the Italian National Pharmacovigilance Network.
    Lavalle C; Di Lullo L; Bellasi A; Ronco C; Radicchia S; Barbera V; Galardo G; Piro A; Magnocavallo M; Straito M; Uguccioni M
    Cardiorenal Med; 2020; 10(4):266-276. PubMed ID: 32353846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.